*CGI-I = Clinical Global Impression Improvement; MAOI = monoamine oxidase inhibitor; NDRI = norepinephrine/dopamine-reuptake inhibitor; QIDS-C16 = 16-item Quick Inventory of Depressive Symptomatology-Clinician Rated; SGA = second-generation antipsychotic; SNRI = serotonin and norepinephrine reuptake inhibitor; SSRI = selective serotonin reuptake inhibitor
Mohamed S, Johnson GR, Chen P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment: the VAST-D randomized clinical trial. JAMA. 2017;318(2):132-145.
- Rush AJ, Trivedi MH, Ibrahim HM, et al. The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression [published correction appears in Biol Psychiatry. 2003;54(5):585]. Biol Psychiatry. 2003;54(5):573-583.
- Mohamed S, Johnson GR, Sevilimedu V, et al. Impact of concurrent posttraumatic stress disorder on outcomes of antipsychotic augmentation for major depressive disorder with a prior failed treatment: VAST-D randomized clinical trial. J Clin Psychiatry. 2020;81(4):19m13038.
This resource is intended for educational purposes only and is intended for US healthcare professionals. Healthcare professionals should use independent medical judgment. All decisions regarding patient care must be handled by a healthcare professional and be made based on the unique needs of each patient.
ABBV-US-01260-MC , V1.0
AbbVie Medical Affairs
Recommended on NP Psych Navigator
NP Spotlight: Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN
A career as a psychiatric nurse practitioner can be replete with challenges and opportunities. The NP Psych Navigator Spotlight is your chance to learn more about nurse practitioners who are working to advance the profession and mental health in general. In this installment of this series, we profile Moushumi Mukerji, MSN, PMHNP-BC, CNM, RN.
Combining Medications to Enhance Depression Outcomes (CO-MED): Acute and Long-term Outcomes of a Single-blind Randomized Study
Major depressive disorder (MDD) is a chronic and disabling condition that affects up to 12% of men and 25% of women. MDD is recurrent, with many patients not achieving complete recovery between depressive episodes. The aim of treatment for MDD is remission, which is associated with improved functioning and prognosis.
Effect of Antidepressant Switching vs Augmentation on Remission Among Patients With Major Depressive Disorder (MDD) Unresponsive to Antidepressant Treatment: the VAST-D Randomized Clinical Trial
Major depressive disorder (MDD) is a chronic condition that affects millions of Americans. Unfortunately, first-line monotherapy does not adequately address depressive symptoms for some MDD patients. The VA Augmentation and Switching Treatments for Improving Depression Outcomes (VAST-D) trial set out to determine the relative effectiveness and safety of 3 next-step treatments for MDD in patients who failed to respond adequately to at least 1 antidepressant treatment trial of adequate dose and duration. This clinical article summary shares the key findings of this landmark trial.